

**Statistics of approved applications for drugs covered by the Community Care Fund
“Subsidy for Eligible Patients to Purchase Ultra-expensive Drugs (Including Those for Treating Uncommon Disorders)”
since its implementation**

Drug items	2018-19					2019-20					2020-21				
	No of cases		Average subsidy amount per case (\$)	Average patient contribution per case (\$)	Total subsidy amount (million)	No of cases		Average subsidy amount per case (\$)	Average patient contribution per case (\$)	Total subsidy amount (million)	No of cases		Average subsidy amount per case (\$)	Average patient contribution per case (\$)	Total subsidy amount (million)
	Full Subsidy	Partial subsidy				Full Subsidy	Partial subsidy				Full Subsidy	Partial subsidy			
Eculizumab ¹	7	3	4,099,276	23,575	40.99	10	4	3,938,357	261,032	55.14	2	3	4,082,154	31,606	20.41
Eculizumab ¹ (Samaritan Fund)											5	4	3,621,747	102,998	32.60
Nusinersen ²	4	-	1,361,118	-	5.44	8	5	3,380,329	466,746	43.94	12	6	2,547,592	637,357	45.86
Tafamidis ³	-	-	-	-	-	-	1	882,548	4,702	0.88	-	1	841,196	46,054	0.84
Dinutuximab Beta ⁴	-	-	-	-	-	-	-	-	-	-	1	6	1,442,496	279,421	10.10

Remarks:

1. The concerned drug and designated clinical indication has been incorporated under the coverage of the Samaritan Fund safety net since 11 July 2020.
2. From 25 September 2018
3. From 13 July 2019
4. From 29 December 2020